Graphite Bio, Inc. GRPH
We take great care to ensure that the data presented and summarized in this overview for Graphite Bio, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in GRPH
Top Purchases
Top Sells
About GRPH
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Insider Transactions at GRPH
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 16
2024
|
Shawn Olsson Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,333
+50.0%
|
$6,666
$2.08 P/Share
|
|
Jul 22
2024
|
Evert B. Schimmelpennink President, CEO and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
45,000
+50.0%
|
$45,000
$1.04 P/Share
|
|
May 14
2024
|
Daniel R. Chevallard Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
3,188
+50.0%
|
$47,820
$15.68 P/Share
|
|
May 13
2024
|
James W Mccollum Director |
BUY
Open market or private purchase
|
Indirect |
31,332
+5.63%
|
$469,980
$15.99 P/Share
|
|
Mar 21
2024
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
64,971
+8.55%
|
$974,565
$15.03 P/Share
|
|
Mar 21
2024
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
933,038
+21.94%
|
$13,995,570
$15.03 P/Share
|
|
Mar 21
2024
|
Ra Capital Management, L.P. |
BUY
Grant, award, or other acquisition
|
Indirect |
3,245,785
+50.0%
|
-
|
|
Mar 21
2024
|
James W Mccollum Director |
BUY
Grant, award, or other acquisition
|
Indirect |
494,233
+26.63%
|
$3,459,631
$7.52 P/Share
|
|
Mar 21
2024
|
James W Mccollum Director |
BUY
Grant, award, or other acquisition
|
Direct |
95,034
+50.0%
|
-
|
|
Mar 21
2024
|
Marc Odrich Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
99,599
+50.0%
|
-
|
|
Mar 21
2024
|
Versant Venture Capital Vi, L.P. |
BUY
Other acquisition or disposition
|
Indirect |
598,203
+41.53%
|
-
|
|
Apr 12
2022
|
Samsara Bio Capital, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
350,000
+3.97%
|
$1,400,000
$4.08 P/Share
|
|
Apr 11
2022
|
Phil Gutry CHIEF BUSINESS OFFICER |
BUY
Open market or private purchase
|
Direct |
5,000
+1.64%
|
$20,000
$4.01 P/Share
|
|
Apr 11
2022
|
Samsara Bio Capital, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
74,464
+0.91%
|
$297,856
$4.07 P/Share
|
|
Jan 24
2022
|
Samsara Bio Capital, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
23,000
+0.29%
|
$184,000
$8.7 P/Share
|
|
Jan 21
2022
|
Samsara Bio Capital, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
100,000
+1.23%
|
$800,000
$8.99 P/Share
|
|
Jan 20
2022
|
Samsara Bio Capital, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
43,105
+0.54%
|
$344,840
$8.92 P/Share
|
|
Jan 19
2022
|
Samsara Bio Capital, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
54,565
+0.69%
|
$491,085
$9.24 P/Share
|
|
Dec 15
2021
|
Samsara Bio Capital, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
22,329
+0.28%
|
$223,290
$10.19 P/Share
|
|
Nov 22
2021
|
Samsara Bio Capital, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
201,685
+2.52%
|
$2,016,850
$10.15 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 3.93M shares |
|---|---|
| Open market or private purchase | 1.03M shares |
| Other acquisition or disposition | 598K shares |
| Exercise of conversion of derivative security | 48.3K shares |